AFM
DRNA

Anson Funds Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Anson Funds Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-99,658
Closed -$287K – 88
2016
Q4 		$287K Buy
+99,658
New +$354K 0.09% 58

Other funds holding DRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Anson Funds Management's DRNA Position: Q1 2017 in Review

Anson Funds Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2017, closing a stake of 99,658 shares — an estimated $287K sold.

Anson Funds Management first reported a position in DRNA in Q4 2016 and held it in 1 quarter. The position peaked at $287K in Q4 2016. 45 funds tracked by Wall St. Rank hold DRNA as of Q1 2017.

  • Anson Funds Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Anson Funds Management sold 99,658 Dicerna Pharmaceuticals, Inc. shares in Q1 2017, an estimated $287K.
  • Anson Funds Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • Anson Funds Management's Dicerna Pharmaceuticals, Inc. position peaked at $287K in Q4 2016.
  • 45 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2017.

Based on Anson Funds Management's 13F filing for Q1 2017, filed 15 May 2017.